Product Information
INCRUSE ELLIPTA 62.5 MCG INH is a brand product labeled by GlaxoSmithKline LLC, priced at $10.2761 per EA under NDC 00173087306. Its NADAC has been published 415 times since Apr 20, 2016.
Strength
62.5 ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173087306
Classification
Brand
Dosage Form
AEROSOL, POWDER
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
UMECLIDINIUM BROMIDEApproval Type
New Drug (NDA)
FDA Application
NDA205382On Market Since
4/30/2014
Pharmacological Classes
Price Statistics
The NADAC for INCRUSE ELLIPTA 62.5 MCG INH has been published 415 times since Apr 20, 2016, and over the history we have for it it has risen 17.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.2761 per EA |
|---|---|
| All-time high | $10.2948 (Jun 11, 2025) |
| All-time low | $8.7322 (Apr 20, 2016) |
| 52-week high | $10.2877 |
| 52-week low | $10.2428 |
| Median price | $9.9663 |
| Average price | $9.8343 |
| Largest weekly change | +9.0% (Oct 12, 2016) |
| Weeks tracked | 415 |
| Tracking since | Apr 20, 2016 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of INCRUSE ELLIPTA 62.5 MCG INH?
The current National Average Drug Acquisition Cost (NADAC) for INCRUSE ELLIPTA 62.5 MCG INH, manufactured by GlaxoSmithKline LLC, is $10.2761 per EA (NDC 00173087306), effective Jun 24, 2026.
How has the price of INCRUSE ELLIPTA 62.5 MCG INH changed over time?
Over the history we have for it, the NADAC for INCRUSE ELLIPTA 62.5 MCG INH has risen 17.7%. It has been tracked across 415 weekly CMS publications since Apr 20, 2016.
What are the highest and lowest recorded NADAC prices for INCRUSE ELLIPTA 62.5 MCG INH?
Since Apr 20, 2016, the NADAC for INCRUSE ELLIPTA 62.5 MCG INH has ranged from a low of $8.7322 (Apr 20, 2016) to a high of $10.2948 (Jun 11, 2025), with a median of $9.9663 per EA.
Are there cheaper alternatives to INCRUSE ELLIPTA 62.5 MCG INH?
1 NADAC-published product shares the same active ingredient, strength, and dosage form as INCRUSE ELLIPTA 62.5 MCG INH, but none are currently priced below it.
Who manufactures INCRUSE ELLIPTA 62.5 MCG INH?
INCRUSE ELLIPTA 62.5 MCG INH (NDC 00173087306) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.
Related Drugs
Same classification